Growing new blood vessels from existing ones ?a process called angiogenesis ?is important in growth, development and wound healing. But it also enables the spread of tumors throughout the body, so researchers have been scrambling for ways to stop angiogenesis in the fight against cancer.
One element critical to blood vessel growth is copper, a vital nutrient that plays important roles in many life processes. Compounds that reduce copper in the body without disrupting the body's normal functions can inhibit the growth of blood vessels ?and some of these compounds are even in clinical trials for use in cancer therapy. Yet, the biological basis for this sensitivity of angiogenesis to copper has been an enigma.
In search of an answer, researchers from the Biosciences and X-ray Science divisions at Argonne and the Department of Medicine, Section of Hematology/Oncology, at the University of Chicago, have used X-ray fluorescence microprobe imaging at the Advanced Photon Source at Argonne, the Western Hemisphere's most brilliant source of X-rays for research. The X-rays allowed the researchers to look at the distribution of copper in both a cell model of angiogenesis and sections of breast tumor tissue rich in blood vessels.
"We found that cells undergoing angiogenesis exhibit a distribution of their cellular copper that is distinctly different from other cells," said Argonne biologist and lead author Lydia Finney. "This discovery may help explain how copper-reducing cancer therapy works." The findings are reported in the current issue of the Proceedings of the National Academy of Sciences, or PNAS.
"We began our study," Finney
'"/>
Source:DOE/Argonne National Laboratory